Open-label Study to Evaluate Clearance of Superficial Basal Cell Carcinoma After Use of Imiquimod 5% Cream

PHASE3CompletedINTERVENTIONAL
Enrollment

169

Participants

Timeline

Start Date

March 31, 2001

Primary Completion Date

April 30, 2007

Study Completion Date

April 30, 2007

Conditions
Superficial Basal Cell Carcinoma
Interventions
DRUG

Imiquimod 5% cream

Aldara (imiquimod) 5% cream - 250 mg / packet - once daily 7 days per week for 6 weeks

Trial Locations (18)

Unknown

Medical Centre, Concord Hospital, Concord

Prince of Wales Hospital, Randwick

Skin Centre, Benowa

South East Dermatology Centre, Carina Heights

105 Fulham Road, Gulliver

Princess Alexandra Hospital, Woolloongabba

Flinders Medical Center, Bedford Park

Queen Elizabeth Hospital, Woodville

Western Hospital, Footscray

Austin & Repartriation Hospital, Heidelburg

Freemantle Dermatology, Fremantle

158 South Terrace, Perth

Subiaco Clinic, Subiaco

103A Mountain Road, Epsom

Birthcare Building, Parnell

Colombo Mansions, Christchurch

Dermatology Practice, Christchurch

Skin Institute Limited, Takapuna

Sponsors
All Listed Sponsors
lead

Graceway Pharmaceuticals, LLC

INDUSTRY